IGLL5 has potential to be a prognostic biomarker and its correlation with immune infiltrates in breast cancer
IGLL5 is a novel prognostic marker for BRCA, and its expression level affects patient survival by modulating TME immune infiltration and metabolic reprogramming. This study provides a theoretical basis for IGLL5-directed immunotherapeutic strategies (e.g., combining PD-1 inhibitors), and its mechanism needs to be verified by multicenter clinical cohorts and functional experiments in the future.
Authors
- Junchao Feng
Institutions
- Soochow University (CN)
- Second Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- American journal of clinical and experimental immunology.
- Published
- 2025-01-01
- DOI
- https://doi.org/10.62347/xlcy5727
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- China National Nuclear Corporation